WHO ICTRP trial
The effectiveness and safety of Anjianning(adalimumab) for the treatment of…
ChiCTR2500104254 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500104254 |
|---|---|
| Public title | The effectiveness and safety of Anjianning(adalimumab) for the treatment of autoimmune diseases in the real-world: A multicenter, prospective, observational study |
| Scientific title | The effectiveness and safety of Anjianning(adalimumab) for the treatment of autoimmune diseases in the real-world: A multicenter, prospective, observational study |
| Primary sponsor | ShangHai GuangHua Hospital of Integrated Traditiona.Chinese and Western Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 4 |
| Countries | China |
| Conditions | Autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis) |
| Interventions | RA group:NA ;AS group:NA ;PsO group:NA |
| Registration date | Jun 13, 2025 |
| Target size | RA group:4500;AS group:4500;PsO group:1000 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: